Stay updated on Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page.

Latest updates to the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe revision label on the page history updated from v3.6.3 to v3.6.4, indicating a small version update to the site.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe latest history entry adds multiple sections to the study record (References, Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Study Status, Study Identification) and logs a new revision dated 2026-07-01 (Revision: v3.6.3), replacing the previous revision 3.6.2.SummaryDifference0.6%

- Check35 days agoChange DetectedThe history now shows Revision: v3.6.2 added and Revision: v3.6.0 removed. This reflects a minor backend/template update to the page.SummaryDifference0.1%

- Check49 days agoChange DetectedThe recruitment status now shows 'No longer looking for participants,' indicating enrollment has ceased for this study. The page also records the current revision as v3.6.0, reflecting the latest update to the study record.SummaryDifference0.2%

- Check56 days agoChange DetectedA new Revision: v3.5.5 has been added to the page's history, and the previous Revision: v3.5.4 entry has been removed.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision: v3.5.4 appears as the new latest entry, replacing v3.5.3 in the study record history. This indicates a minor update to the record metadata rather than substantive changes to study content.SummaryDifference0.1%

Stay in the know with updates to Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page.